Compare Marathon Petroleum Corp (MPC) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Petroleum Corp vs GeneDx Holdings Corp — how do they compare? Marathon Petroleum Corp trades at $401.85 (market cap $111.70B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: Marathon Petroleum Corp is far larger — about 43.6× GeneDx Holdings Corp's market cap, and Marathon Petroleum Corp pays a 1.01% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| MPC | WGS | |
|---|---|---|
Market Cap | $111.70B | $2.56B |
Sector | Energy | Technology |
52-Week High | $399.44 | $167.51 |
52-Week Low | $162.63 | $34.51 |
Enterprise Value | $138.23B | $2.60B |
Dividend Yield | 1.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $397.77, up 2.28% today, and is near its 52-week high. The stock shows strong momentum with bullish technical signals and has consistently beaten earnings estimates in recent quarters. Key fundamentals include a P/E of 13.79, robust ROE of 47.9%, and positive cash flow trends. Recent news highlights refinery efficiency gains and geopolitical tailwinds boosting energy sector sentiment.
Outlook remains positive given strong analyst consensus (78.79% buy ratings) and projected revenue growth to $153.6B in 2026. Risks include cyclical energy demand volatility and rising debt-to-asset ratios. The stock offers value through earnings momentum but faces headwinds from macroeconomic uncertainty.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
